SG11201809497RA - Processes for preparing phosphorodiamidate morpholino oligomers - Google Patents
Processes for preparing phosphorodiamidate morpholino oligomersInfo
- Publication number
- SG11201809497RA SG11201809497RA SG11201809497RA SG11201809497RA SG11201809497RA SG 11201809497R A SG11201809497R A SG 11201809497RA SG 11201809497R A SG11201809497R A SG 11201809497RA SG 11201809497R A SG11201809497R A SG 11201809497RA SG 11201809497R A SG11201809497R A SG 11201809497RA
- Authority
- SG
- Singapore
- Prior art keywords
- street
- international
- cambridge
- oligomer
- processes
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 241001635911 Sarepta Species 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 235000006679 Mentha X verticillata Nutrition 0.000 abstract 1
- 235000002899 Mentha suaveolens Nutrition 0.000 abstract 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 abstract 1
- -1 PHOSPHORODIAMIDATE MORPHOLINO Chemical class 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/6533—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341049P | 2016-05-24 | 2016-05-24 | |
| US201662340953P | 2016-05-24 | 2016-05-24 | |
| US201662357166P | 2016-06-30 | 2016-06-30 | |
| US201662357134P | 2016-06-30 | 2016-06-30 | |
| US201762508256P | 2017-05-18 | 2017-05-18 | |
| PCT/US2017/040318 WO2017205880A1 (en) | 2016-05-24 | 2017-06-30 | Processes for preparing phosphorodiamidate morpholino oligomers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809497RA true SG11201809497RA (en) | 2018-12-28 |
Family
ID=60412589
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809497RA SG11201809497RA (en) | 2016-05-24 | 2017-06-30 | Processes for preparing phosphorodiamidate morpholino oligomers |
| SG10202101836TA SG10202101836TA (en) | 2016-05-24 | 2017-06-30 | Processes for preparing phosphorodiamidate morpholino oligomers |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202101836TA SG10202101836TA (en) | 2016-05-24 | 2017-06-30 | Processes for preparing phosphorodiamidate morpholino oligomers |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230045831A1 (de) |
| EP (1) | EP3463363A4 (de) |
| AU (1) | AU2017270975B2 (de) |
| BR (1) | BR112018074340A2 (de) |
| CA (1) | CA3024456A1 (de) |
| CO (1) | CO2018013834A2 (de) |
| IL (1) | IL263044B2 (de) |
| MA (1) | MA45183A (de) |
| MX (1) | MX2018014123A (de) |
| SA (1) | SA518400467B1 (de) |
| SG (2) | SG11201809497RA (de) |
| WO (1) | WO2017205880A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| MA45362A (fr) | 2016-05-24 | 2019-04-10 | Sarepta Therapeutics Inc | Procédés de préparation d'oligomères morpholino de phosphorodiamidate |
| DK3464306T3 (da) | 2016-05-24 | 2024-05-21 | Sarepta Therapeutics Inc | Fremgangsmåder til fremstilling af phosphorodiamidat-morpholino-oligomerer |
| MX2021008539A (es) | 2016-05-24 | 2022-10-18 | Sarepta Therapeutics Inc | Procesos para preparar oligomeros. |
| US11472824B2 (en) | 2016-05-24 | 2022-10-18 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| EP3630789A4 (de) | 2017-06-02 | 2021-06-16 | Wave Life Sciences Ltd. | Oligonucleotidzusammensetzungen und verfahren zu ihrer verwendung |
| JP2020522510A (ja) | 2017-06-02 | 2020-07-30 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド組成物及びその使用方法 |
| WO2021025899A1 (en) | 2019-08-02 | 2021-02-11 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer pharmaceutical compositions |
| JP2023526975A (ja) * | 2020-05-22 | 2023-06-26 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物及びその方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| JP2528107B2 (ja) | 1985-03-15 | 1996-08-28 | サマ−トン，ジエ−ムス | ポリヌクレオチド測定試薬と方法 |
| WO1990002749A1 (en) | 1988-09-01 | 1990-03-22 | Forskningscenter Risø | Peptide synthesis method and solid support for use in the method |
| US7759513B2 (en) * | 2003-02-21 | 2010-07-20 | Nigu Chemie Gmbh | Photolabile protective groups for improved processes to prepare oligonucleotide arrays |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| US9371348B2 (en) * | 2006-11-27 | 2016-06-21 | The Trustees Of The University Of Pennsylvania | Photocleavable oligonucleotide and uses thereof |
| US8299206B2 (en) | 2007-11-15 | 2012-10-30 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
| CN101861318A (zh) | 2007-11-15 | 2010-10-13 | Avi生物制药公司 | 合成吗啉代低聚物的方法 |
| US8076476B2 (en) | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| KR20200133284A (ko) * | 2010-05-28 | 2020-11-26 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| WO2012043730A1 (ja) | 2010-09-30 | 2012-04-05 | 日本新薬株式会社 | モルホリノ核酸誘導体 |
| US9920084B2 (en) * | 2011-08-23 | 2018-03-20 | The Royal Institution For The Advancement Of Learning/Mcgill University | Ionic tags for synthesis of oligoribonucleotides |
| KR20140097398A (ko) * | 2011-11-18 | 2014-08-06 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트 |
| US9944926B2 (en) * | 2011-11-30 | 2018-04-17 | Sarepta Therapeutics, Inc. | Induced exon inclusion in spinal muscle atrophy |
| EP2820155B1 (de) * | 2012-02-28 | 2017-07-26 | Population Genetics Technologies Ltd. | Verfahren zur befestigung einer zählersequenz an einer nucleinsäureprobe |
| EP2970964B8 (de) * | 2013-03-14 | 2019-03-06 | Sarepta Therapeutics, Inc. | Verbesserte exon-skipping-zusammensetzungen zur behandlung von muskeldystrophie |
-
2017
- 2017-06-30 MA MA045183A patent/MA45183A/fr unknown
- 2017-06-30 IL IL263044A patent/IL263044B2/en unknown
- 2017-06-30 MX MX2018014123A patent/MX2018014123A/es unknown
- 2017-06-30 SG SG11201809497RA patent/SG11201809497RA/en unknown
- 2017-06-30 WO PCT/US2017/040318 patent/WO2017205880A1/en unknown
- 2017-06-30 SG SG10202101836TA patent/SG10202101836TA/en unknown
- 2017-06-30 EP EP17803761.0A patent/EP3463363A4/de active Pending
- 2017-06-30 CA CA3024456A patent/CA3024456A1/en active Pending
- 2017-06-30 BR BR112018074340-2A patent/BR112018074340A2/pt active Search and Examination
- 2017-06-30 AU AU2017270975A patent/AU2017270975B2/en active Active
-
2018
- 2018-11-20 SA SA518400467A patent/SA518400467B1/ar unknown
- 2018-12-19 CO CONC2018/0013834A patent/CO2018013834A2/es unknown
-
2022
- 2022-06-15 US US17/841,185 patent/US20230045831A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL263044A (en) | 2018-12-31 |
| EP3463363A1 (de) | 2019-04-10 |
| SA518400467B1 (ar) | 2023-03-12 |
| IL263044B2 (en) | 2024-06-01 |
| AU2017270975B2 (en) | 2021-04-15 |
| MA45183A (fr) | 2019-04-10 |
| CO2018013834A2 (es) | 2019-01-18 |
| MX2018014123A (es) | 2019-04-29 |
| IL263044B1 (en) | 2024-02-01 |
| SG10202101836TA (en) | 2021-03-30 |
| US20230045831A1 (en) | 2023-02-16 |
| WO2017205880A1 (en) | 2017-11-30 |
| CA3024456A1 (en) | 2017-11-30 |
| AU2017270975A1 (en) | 2019-01-17 |
| EP3463363A4 (de) | 2020-02-19 |
| BR112018074340A2 (pt) | 2019-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201804443UA (en) | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201408054RA (en) | Pegylated oxm variants | |
| SG11201408261UA (en) | Syringe | |
| SG11201408821SA (en) | Selective pi3k delta inhibitors | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201404836QA (en) | Long-acting coagulation factors and methods of producing same | |
| SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
| SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy |